Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 5.47% is 100% above its 5-year average of 2.73%, near the high end of its 5-year range (0.18%–5.47%).
As of the fiscal period ended Tuesday, June 30, 2026. 33.99% above its 12-month average of 4.08%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 5.47%.
DEBT TO ASSETS RATIO
5.47%
DEBT TO ASSETS RATIO AVG TTM
4.08%
DEBT TO ASSETS RATIO AVG 3Y
3.64%
DEBT TO ASSETS RATIO AVG 5Y
2.73%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+33.99%
CURRENT VS 3Y AVG
+50.14%
CURRENT VS 5Y AVG
+99.92%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 605 covered companies
CURRENT VS SECTOR MEDIAN
+5367.32%
vs the sector median at left
Keros Therapeutics, Inc.
Market Cap
$224.74M
Debt to Assets Ratio
5.47%
TTM Avg
4.08%
3Y Avg
3.64%
5Y Avg
2.73%
Market Cap
$225.24M
Debt to Assets Ratio
0.17%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$218.58M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$215.30M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$235.83M
Debt to Assets Ratio
0.15%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | $224.74M | 5.47% | 4.08% | 3.64% | 2.73% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | 0.17% | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $228.33M | 0.75% | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $230.05M | 0.10% | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $218.58M | 0.00% | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $215.30M | 0.02% | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $215.11M | 0.02% | N/A | N/A | N/A |
| BioAge Labs Inc. (BIOA)vs › | $234.54M | 0.01% | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.83M | 0.15% | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $212.94M | 0.12% | N/A | N/A | N/A |
Debt/Assets
5.5%
Debt/Equity
0.06
Current Ratio
21.96
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 5.47% |
| 2026-03-31 | 5.22% |
| 2025-12-31 | 4.99% |
| 2025-09-30 | 2.35% |
| 2025-06-30 | 2.37% |
| 2025-03-31 | 2.35% |
| 2024-12-31 | 3.06% |
| 2024-09-30 | 3.33% |
| 2024-06-30 | 3.07% |
| 2024-03-31 | 2.92% |
| 2023-12-31 | 3.90% |
| 2023-09-30 | 4.39% |
| 2023-06-30 | 3.92% |
| 2023-03-31 | 3.64% |
| 2022-12-31 | 4.32% |
| 2022-09-30 | 0.18% |
| 2022-06-30 | 0.30% |
| 2022-03-31 | 0.38% |
| 2021-12-31 | 0.43% |
| 2021-09-30 | 0.56% |
| 2021-06-30 | 0.28% |
| 2021-03-31 | 0.31% |
| 2020-12-31 | 0.33% |
| 2020-09-30 | 0.72% |
| 2020-06-30 | 0.73% |
| 2020-03-31 | 126.93% |
| 2019-12-31 | 11.64% |
